🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Recurrent Solid Tumor

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). NCT06607692Phase 1, Phase 21 site📍 Boadilla del Monte Fundación de investigación HM · Tests: Olaparib; 177Lu-DOTATATE COAST Therapy in Advanced Solid Tumors and Prostate Cancer NCT05036226Phase 1, Phase 21 site📍 Charleston Medical University of South Carolina · Tests: Hydroxychloroquine, Metformin, Sirolimus, Hydroxychloroquine, Metformin, Sirolimus, Dasatanib, Hydroxychloroquine, Metf… Personalized Neoantigen Peptide Vaccines for Solid Tumors NCT07002203Phase 1, Phase 21 site📍 Bangkok Seqker Biosciences, Inc. · Tests: Personalized Neoantigen Peptide Vaccine IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors NCT05958121Phase 1, Phase 229 sites📍 Heidelberg📍 Heidelberg📍 Mannheim Immatics Biotechnologies GmbH · Tests: IMA402, IMA402 and checkpoint inhibitor, IMA402 and chemotherapy, IMA402 and IMA401, IMA402 and monoclonal antibody A Clinical Study of CHT101 in CD70-Positive Advanced Solid Tumors NCT06730659Phase 11 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: CHT101 EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC NCT07617805Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: EGFR/HER2 Dual-Target CAR-NK Cells, Fludarabine, Cyclophosphamide A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1) NCT05865002Phase 137 sites📍 Vijayawada📍 Visakhapatnam📍 Chandigarh Aurigene Discovery Technologies Limited · Tests: AUR107 Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study NCT07405086Phase 41 site📍 Portland OHSU Knight Cancer Institute · Tests: Biospecimen Collection, Immune Checkpoint Inhibitor Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial NCT04693468Phase 11 site📍 Houston M.D. Anderson Cancer Center · Tests: Axitinib, Crizotinib, Palbociclib Isethionate, Talazoparib Tosylate CT-95 in Advanced Cancers Associated With Mesothelin Expression NCT06756035Phase 19 sites📍 Denver📍 Chicago📍 Grand Rapids Context Therapeutics Inc. · Tests: CT-95 Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors NCT04777994Phase 130 sites📍 Tucson📍 New Haven📍 Baltimore Calico Life Sciences LLC · Tests: ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Deat… Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors NCT06408688Phase 44 sites📍 Baden📍 Basel📍 Liestal University Hospital, Basel, Switzerland · Tests: Immune checkpoint inhibitors plus Iscador® Qu., Immune Checkpoint Inhibitors A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. NCT06022029Phase 116 sites📍 Los Angeles📍 Tamarac📍 Canton OncoNano Medicine, Inc. · Tests: ONM-501, Cemiplimab A Study of PYX-201 in Advanced Solid Tumors NCT05720117Phase 129 sites📍 Scottsdale📍 Los Angeles📍 Denver Pyxis Oncology, Inc · Tests: PYX-201 Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors NCT06320405Phase 1, Phase 21 site📍 Portland OHSU Knight Cancer Institute · Tests: Axatilimab, Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors NCT07277413Phase 123 sites📍 Goodyear📍 Phoenix📍 Duarte IDEAYA Biosciences · Tests: IDE892, IDE397 ML-016 in Advanced Cancer With Lung and/or Liver Involvement NCT07723482Phase 1, Phase 23 sites📍 Miranda📍 Wollongong📍 Buderim BrYet US, Inc. · Tests: ML-016 Collection and Storage of Tissue and Blood Samples From Patients With Cancer NCT02474160n/a140 sites📍 Birmingham📍 Fort Smith📍 Arroyo Grande National Cancer Institute LAO · Tests: Cytology Specimen Collection Procedure APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors NCT05701306Phase 1, Phase 23 sites📍 Guangzhou📍 Wuhan📍 Tianjin Ascentage Pharma Group Inc. · Tests: APG-115, APG-2575 Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer NCT07667400Phase 1, Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: SX-682, DTX CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors NCT05410717Phase 11 site📍 Guangzhou Second Affiliated Hospital of Guangzhou Medical University · Tests: Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors NCT03686124Phase 1, Phase 221 sites📍 Stanford📍 Aurora📍 Miami Immatics US, Inc. · Tests: IMA203 Product, IMA203 product- flat dose, IMA203CD8 Product, Nivolumab, IMADetect® KSH01-TCRT Solid Tumors NCT05539833EARLY Phase 11 site📍 Nanning TCRx Therapeutics Co.Ltd · Tests: KSH01 injection Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors NCT03934372Phase 1, Phase 223 sites📍 Ghent📍 Paris📍 Paris Incyte Biosciences International Sàrl · Tests: Ponatinib A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors NCT06063681Phase 13 sites📍 Randwick📍 Clayton📍 Frankston Stingray Therapeutics · Tests: SR-8541A, Immune checkpoint inhibitor (ICI) IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors NCT05039801Phase 11 site📍 Houston M.D. Anderson Cancer Center · Tests: Bevacizumab, Glutaminase-1 Inhibitor IACS-6274, Paclitaxel, Capivasertib Exploratory Study of Super DC Cell Injection in Preventing Recurrence After Radical Surgery for Tumors NCT07146672Phase 1, Phase 21 site📍 Shanghai Shanghai Cell Therapy Group Co.,Ltd · Tests: Super DC Vaccine Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF NCT03604315Phase 11 site📍 Houston M.D. Anderson Cancer Center · Tests: Computed Tomography, Computed Tomography, Fludeoxyglucose F-18, Fluorine F 18 Fluorthanatrace, Positron Emission Tomogr… Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors NCT07584499Phase 11 site📍 Guangzhou Sun Yat-sen University · Tests: Becotatug Vedotin Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors NCT05270213Phase 114 sites📍 Scottsdale📍 Tucson📍 Palo Alto Riboscience, LLC. · Tests: RBS2418, Pembrolizumab, Other approved anti-cancer therapy
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy